Apogee Therapeutics’ Price Target Raised to $95 with 30% Upside Potential
Wedbush increased Apogee Therapeutics’ price target to $95, maintaining an Outperform rating and implying 30% upside. The company reported a FY25 net loss of $255.8 million and expects Phase 2 APEX dose‐ranging induction data in Q2 2026, with Phase 3 trials slated for H2 and cash runway into mid-2028.
1. Wedbush Price Target Increase
Wedbush raised Apogee’s price target from $90 to $95, preserving an Outperform rating that implies roughly 30% upside, reflecting confidence in the firm’s clinical programs and near-term catalysts.
2. FY25 Financial Results
Apogee reported a FY25 net loss of $255.8 million, up from $182.1 million in the prior year, driven by R&D investments across its biologics pipeline.
3. Clinical Pipeline Developments
The company reaffirmed guidance on its 52-week Phase 2 APEX study, expects dose-ranging induction data in Q2 2026, plans Phase 3 trial starts in H2 2026 and a head-to-head APG279 readout versus DUPIXENT in late 2026.
4. Financial Runway and Strategic Outlook
With cash runway into the second half of 2028, Apogee plans to advance expansion indications for asthma and eosinophilic esophagitis, aiming to position zumilokibart as a pipeline-in-a-product across inflammatory and immune diseases.